Active, not recruitingPhase 3NCT04821622

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pfizer
Principal Investigator
Pfizer CT.gov Call Center
Pfizer
Intervention
talazoparib plus enzalutamide(drug)
Enrollment
599 enrolled
Eligibility
18 years · MALE
Timeline
20212027

Study locations (30)

Collaborators

Astellas Pharma Inc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04821622 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia

← Back to all trials